Exuma Biotechnology

EXUMA Biotech, founded in 2015 and based in Coral Gables, Florida, is advancing a suite of proprietary technologies designed to revolutionize cell and gene therapy delivery. The company's core platforms include the rPOC SC for ex vivo chemotherapy-free CAR-T and the GCAR platform for in vivo, off-the-shelf, and rechargeable CAR-T therapies, supported by enabling technologies like CD3-Targeted LVV and FITNESS DRIVER. With a clinical-stage pipeline, seasoned leadership, and a focus on expanding the settings of care, EXUMA is positioning itself to address significant unmet needs in oncology and autoimmunity.

Suite of platforms for gene vector delivery and cell therapy engineering, including rPOC SC for ex vivo chemotherapy-free CAR-T, GCAR for in vivo/off-the-shelf/rechargeable CAR-T, CD3-Targeted LVV, FITNESS DRIVER transgene, Tumor Metabolism Regulated (TMR) CARs, and Synthetic CAR Ligands (SCL).

EXUMA competes in the crowded cell therapy space against large pharma (e.g., Novartis, Gilead) and biotechs focused on next-gen CAR-T (e.g., Allogene with allogeneic approaches, Caribou Biosciences with CRISPR-edited cells). Its differentiation lies in its integrated platform aiming for in vivo delivery and chemotherapy-free regimens.